2005
The generalizability of observational data to elderly patients was dependent on the research question in a systematic review
Gross CP, Garg PP, Krumholz HM. The generalizability of observational data to elderly patients was dependent on the research question in a systematic review. Journal Of Clinical Epidemiology 2005, 58: 130-137. PMID: 15680745, DOI: 10.1016/j.jclinepi.2004.10.001.Peer-Reviewed Original ResearchConceptsCooperative Cardiovascular ProjectIntracranial hemorrhageSystematic reviewBeta-blocker useElderly patientsAngiography useCommunity patientsAtrial fibrillationRisk factorsObservational studyOutcome measuresRCT dataPresentation delayGlobal UtilizationT-PAPatientsSimilar predictorsTreatment variationStudy questionsCCP dataGUSTOHemorrhageReviewFibrillationAbsolute rate
2003
Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study
Krumholz HM, Gross CP, Peterson ED, Barron HV, Radford MJ, Parsons LS, Every NR. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study. American Heart Journal 2003, 146: 839-847. PMID: 14597933, DOI: 10.1016/s0002-8703(03)00408-3.Peer-Reviewed Original ResearchConceptsCooperative Cardiovascular ProjectRandomized trialsExclusion criteriaEligibility criteriaMortality rateClinical practiceKillip class III/IVClass III/IVOccluded Coronary Arteries (GUSTO-I) trialCoronary Arteries trialHospital mortality rateMyocardial infarction careTrial eligibility criteriaHigh mortality rateRetrospective registryBaseline characteristicsClinical characteristicsElderly patientsOlder patientsCCP patientsClinical presentationClinical eventsMyocardial infarctionHealthy cohortHospital characteristics
2000
Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: Analysis of the Cooperative Cardiovascular Project
Berger A, Radford M, Krumholz H. Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: Analysis of the Cooperative Cardiovascular Project. American Heart Journal 2000, 139: 985-992. PMID: 10827378, DOI: 10.1067/mhj.2000.105703.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnistreplaseElectrocardiographyFemaleHumansMaleMyocardial InfarctionPatient AdmissionPlasminogen ActivatorsQuality Indicators, Health CareRetrospective StudiesRisk FactorsStreptokinaseSurvival RateThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorTreatment FailureUnited StatesConceptsAcute myocardial infarctionHospital arrivalElderly patientsMortality rateMyocardial infarctionCardiology/American Heart Association guidelinesAmerican Heart Association guidelinesAdministration of thrombolysisHistory of hypertensionHeart Association guidelinesCooperative Cardiovascular Project databaseCooperative Cardiovascular ProjectCardiac catheterization laboratoryReperfusion therapyClinical characteristicsHeart failureST elevationThrombolytic therapyAssociation guidelinesHospital characteristicsCatheterization laboratoryAmerican CollegeThrombolysisPatientsRapid treatment
1995
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
Kalish S, Gurwitz J, Krumholz H, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Journal Of General Internal Medicine 1995, 10: 321-330. PMID: 7562123, DOI: 10.1007/bf02599951.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTissue plasminogen activatorAcute myocardial infarctionAdditional quality-adjusted life yearMyocardial infarctionGUSTO trialThrombolytic therapyOne-year mortality dataOccluded Coronary Arteries (GUSTO-I) trialMortality dataPlasminogen activatorLong-term medical costsCoronary Arteries trialOne-year mortalityUse of streptokinaseInferior wall infarctionCost-effective therapyCost-effectiveness modelDecision analysis modelSurvival benefitSymptom onsetClinical outcomesRelative survival advantageThrombolytic agentsSurvival advantage
1992
Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction
Krumholz H, Pasternak R, Weinstein M, Friesinger G, Ridker P, Tosteson A, Goldman L. Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction. New England Journal Of Medicine 1992, 327: 7-13. PMID: 1598117, DOI: 10.1056/nejm199207023270102.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyRisk of deathMyocardial infarctionElderly patientsPatients 75 yearsST-segment elevationOnset of symptomsUse of streptokinaseOne-way sensitivity analysesDecision analytic modelYears of lifeCost-effective treatmentRelative reductionHospital deathStreptokinase therapyOlder patientsClinical circumstancesThrombolytic agentsInfarctionPatientsCost effectivenessTherapyLack of consensusStreptokinase